Non-neutralizing antibodies in prevention of HIV infection

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials

(2012) D. C. Montefiori et al.   JOURNAL OF INFECTIOUS DISEASES

Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design

(2012) Mattia Bonsignori et al.   JOURNAL OF VIROLOGY

A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced Fc RIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques

(2012) B. Moldt et al.   JOURNAL OF VIROLOGY

Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144

(2012) Merlin L Robb et al.   LANCET INFECTIOUS DISEASES

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

(2012) Morgane Rolland et al.   NATURE

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

(2012) Dan H. Barouch et al.   NATURE

B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study

(2012) Barton F Haynes et al.   NATURE BIOTECHNOLOGY

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Detection of Recent HIV-1 Infection Using a New Limiting-Antigen Avidity Assay: Potential for HIV-1 Incidence Estimates and Avidity Maturation Studies

(2012) Yen T. Duong et al.   PLoS One

Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells

(2012) G.-M. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses

(2012) D. R. Burton et al.   SCIENCE

HIV-Specific Antibodies Capable of ADCC Are Common in Breastmilk and Are Associated with Reduced Risk of Transmission in Women with High Viral Loads

(2012) Jennifer Mabuka et al.   PLoS Pathogens

Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles

(2011) Paul A. Goepfert et al.   JOURNAL OF INFECTIOUS DISEASES

Prevention of Infection by a Granulocyte-Macrophage Colony-Stimulating Factor Co-Expressing DNA/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine

(2011) Lilin Lai et al.   JOURNAL OF INFECTIOUS DISEASES

An HIV-1 gp120 Envelope Human Monoclonal Antibody That Recognizes a C1 Conformational Epitope Mediates Potent Antibody-Dependent Cellular Cytotoxicity (ADCC) Activity and Defines a Common ADCC Epitope in Human HIV-1 Serum

(2011) G. Ferrari et al.   JOURNAL OF VIROLOGY

A Panel of IgG1 b12 Variants with Selectively Diminished or Enhanced Affinity for Fc  Receptors To Define the Role of Effector Functions in Protection against HIV

(2011) B. Moldt et al.   JOURNAL OF VIROLOGY

Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors

(2011) M. Bonsignori et al.   JOURNAL OF VIROLOGY

Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody

(2011) D. R. Burton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure

(2011) A. W. Chung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

(2011) X. Wu et al.   SCIENCE

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

(2011) S. Khurana et al.   Science Translational Medicine

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses

(2011) Lilin Lai et al.   VACCINE

Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1

(2011) Iliyana Mikell et al.   PLoS Pathogens

Development of Two Avidity-Based Assays to Detect Recent HIV Type 1 Seroconversion Using a Multisubtype gp41 Recombinant Protein

(2010) Xierong Wei et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates

(2010) Christopher Sundling et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples

(2010) Margaret E. Ackerman et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine

(2010) S. Kannanganat et al.   JOURNAL OF IMMUNOLOGY

Multiple Vaccine-Elicited Nonneutralizing Antienvelope Antibody Activities Contribute to Protective Efficacy by Reducing both Acute and Chronic Viremia following Simian/Human Immunodeficiency Virus SHIV89.6P Challenge in Rhesus Macaques

(2010) P. Xiao et al.   JOURNAL OF VIROLOGY

Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 Adjuvant

(2010) S. W. Barnett et al.   JOURNAL OF VIROLOGY

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

(2010) Hugo Mouquet et al.   NATURE

Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers

(2009) Olivier Lambotte et al.   AIDS

In Vivo gp41 Antibodies Targeting the 2F5 Monoclonal Antibody Epitope Mediate Human Immunodeficiency Virus Type 1 Neutralization Breadth

(2009) X. Shen et al.   JOURNAL OF VIROLOGY

Preclinical Studies of Human Immunodeficiency Virus/AIDS Vaccines: Inverse Correlation between Avidity of Anti-Env Antibodies and Peak Postchallenge Viremia

(2009) J. Zhao et al.   JOURNAL OF VIROLOGY

Human Immunodeficiency Virus Type 1 Is Trapped by Acidic but Not by Neutralized Human Cervicovaginal Mucus

(2009) S. K. Lai et al.   JOURNAL OF VIROLOGY

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target

(2009) L. M. Walker et al.   SCIENCE

Potent Human Immunodeficiency Virus-Neutralizing and Complement Lysis Activities of Antibodies Are Not Obligatorily Linked

(2008) M. Huber et al.   JOURNAL OF VIROLOGY

Correlation of Vaccine-Elicited Systemic and Mucosal Nonneutralizing Antibody Activities with Reduced Acute Viremia following Intrarectal Simian Immunodeficiency Virus SIVmac251 Challenge of Rhesus Macaques

(2008) R. Hidajat et al.   JOURNAL OF VIROLOGY

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

(2008) Susan P Buchbinder et al.   LANCET